The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

As the first and only approved drug for post-partum depression, the offer undervalues Zurzuvae, the analyst tells investors in a research note. The firm thinks the drug is off to a slow ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...